AstraZeneca plc (ADR) (AZN) engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. Its marketed products comprise Accolate, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp, Duaklir Genuair, Eklira Genuair/Tudorza/Bretaris, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Rhinocort, Symbicort pMDI, and Symbicort Turbuhaler for respiratory, inflammation, and autoimmunity diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL, Tenormin3, and Zestril4 for cardiovascular disease; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic disease. The companys marketed products also include Arimidex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex, in addition to Casodex, Cosudex for oncology disease; Fluenz/FluMist, Fluenz Tetra/FluMist Quadrivalent1, Merrem/Meronem2, Synagis3, and Zinforo4 for infection disease; Diprivan, EMLA, Movantik/Moventig, Naropin, Seroquel IR, Seroquel XR, Vimovo1, Xylocaine, and Zomig for neuroscience disease; and Losec/Prilosec and Nexium for gastrointestinal disease. It serves primary care and specialty care physicians through distributors and local representative offices. The companys pipeline includes 146 projects, of which 125 are in the clinical phase of development. It has partnershipagreements with Celgene Corporation; Immunocore Limited; Heptares Ltd.; Foundation Medicine, Inc., French National Institute of Health and Medical Research (Inserm); and FibroGen and Astellas, in addition to a research agreement with Eli Lilly. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
Medtronic PLC (MDT) declared recently that it will report financial results for its third quarter of fiscal year 2017 on Tuesday, February 21, 2017. A news release will be issued at about 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company`s third quarter of fiscal year 2017, which ended on Friday, January 27, 2017.
Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its third quarter of fiscal year 2017. The webcast can be accessed at http://shareholderrelations.medtronic.com on February 21, 2017.
Within 24 hours of the webcast, a replay and transcript of the prepared remarks will be available by clicking on the Shareholder Events link at http://shareholderrelations.medtronic.com.
Looking ahead, Medtronic plans to report its fiscal 2017 fourth quarter financial results on Thursday, May 25, 2017, and for fiscal year 2018, the company plans to report its fiscal first and second quarter financial results on Tuesday, August 22, 2017, and Tuesday, November 21, 2017, respectively. Additional details will be offered closer to the specific quarterly earnings release date.